UIP OR NOT UIP PATTERN: THAT IS NOT THE ONLY QUESTION!

Similar documents
Patient with IPF and no honeycombing on HRCT. Case 1 Demosthenes Bouros, Vasilios Tzilas University of Athens

5/9/2015. Multi-disciplinary Approach to Diffuse Lung Disease: The Imager s Perspective. No, I am not a pulmonologist! Radiology

A case of a patient with IPF treated with nintedanib. Prof. Kreuter and Prof. Heussel

DIAGNOSTIC NOTE TEMPLATE

Differential diagnosis

Case Presentations in ILD. Harold R. Collard, MD Department of Medicine University of California San Francisco

INTERSTITIAL LUNG DISEASE. Radhika Reddy MD Pulmonary/Critical Care Long Beach VA Medical Center January 5, 2018

Patient with FVC>90% predicted. Demosthenes Bouros, Vasilios Tzilas University of Athens

A Review of Interstitial Lung Diseases. Paul J. Wolters, MD Associate Professor Department of Medicine University of California San Francisco

4/17/2010 C ini n ca c l a Ev E a v l a ua u t a ion o n of o ILD U dat a e t e i n I LDs

11/10/2014. Multi-disciplinary Approach to Diffuse Lung Disease: The Imager s Perspective. Radiology

A Review of Interstitial Lung Diseases

Connective Tissue Disorder- Associated Interstitial Lung Disease (CTD-ILD) and Updates

TBLB is not recommended as the initial biopsy option in cases of suspected IPF and is unreliable in the diagnosis of rare lung disease (other than

IDIOPATHIC PULMONARY FIBROSIS Guidelines for Diagnosis and Management

ERS 2016 Congress Highlights Interstitial Lung Disease (ILD)

June 2013 Pulmonary Case of the Month: Diagnosis Makes a Difference. Lewis J. Wesselius, MD 1 Henry D. Tazelaar, MD 2

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Diagnosing Idiopathic Pulmonary Fibrosis on Evidence-Based Guidelines

CTD-related Lung Disease

Disclosures. Clinical Approach: Evaluating CTD-ILD for the pulmonologist. ILD in CTD. connective tissue disease or collagen vascular disease

COI: no conflicts of interest to declare

Initial presentation of idiopathic pulmonary fibrosis as an acute exacerbation

Outline Definition of Terms: Lexicon. Traction Bronchiectasis

International consensus statement on idiopathic pulmonary fibrosis

The Egyptian Journal of Hospital Medicine (July 2017) Vol.68 (2), Page

New respiratory symptoms and lung imaging findings in a woman with polymyositis

Diagnostic challenges in IPF

Myositis and Your Lungs

IPF: Epidemiologia e stato dell arte

Non-neoplastic Lung Disease II

BRONCHOALVEOLAR LAVAGE (BAL) Venerino Poletti Osp GB Morgagni, Forlì (I)

Financial disclosure COMMON DIAGNOSES IN HRCT. High Res Chest HRCT. HRCT Pre test. I have no financial relationships to disclose. Anatomy Nomenclature

Pulmonary manifestations of CTDs Diagnosis, differential diagnosis and treatment

Summary: Key Learning Points, Clinical Strategies, and Future Directions

INTERSTITIAL LUNG DISEASE Dr. Zulqarnain Ashraf

Current approaches to the diagnosis and treatment of idiopathic pulmonary fibrosis in Europe: the AIR survey

Interstitial Lung Disease

Overview of Idiopathic Pulmonary Fibrosis: Diagnosis and Therapy

IPF - Inquadramento clinico

Diffuse Interstitial Lung Diseases: Is There Really Anything New?

INTERSTITIAL LUNG DISEASES: FOCUS ON IDIOPATHIC PULMONARY FIBROSIS (IPF)

Lines and crackles. Making sense of ILD

Eosinophils and effusion: a clinical conundrum

Annual Rheumatology & Therapeutics Review for Organizations & Societies

Sarcoidosis Registry Proforma

Ontario s Referral and Listing Criteria for Adult Lung Transplantation

Update on Therapies for Idiopathic Pulmonary Fibrosis. Outline

Idiopathic Pulmonary of Care

Bronkhorst colloquium Interstitiële longziekten. Katrien Grünberg, klinisch patholoog

Bronchoalveolar Lavage and Histopathologic Diagnosis Based on Biopsy

PL-7 and Anti-Jo-1 Antibodies. publication is available at link.sp

Interstitial Lung Diseases(ILD) By : Dr. Shaher M. Samrah Done by : Ibrahim M. sun

An earlier and more confident diagnosis of idiopathic pulmonary fibrosis

SCLERODERMA LUNG DISEASE: WHAT THE PATIENT SHOULD KNOW

Scholars Journal of Medical Case Reports

Eosinophilic lung diseases

Neglected evidence in idiopathic pulmonary fibrosis and the importance of early diagnosis and treatment

Case 1 : Question. 1.1 What is the intralobular distribution? 1. Centrilobular 2. Perilymphatic 3. Random

Changes in HRCT findings in patients with respiratory bronchiolitis-associated interstitial lung disease after smoking cessation

11/19/2012. The spectrum of pulmonary diseases in HIV-infected persons is broad.

Guidelines for Diagnosis and Treatment of IPF

Interstitial Lung Disease (ILD)

Combined Pulmonary Fibrosis and Emphysema - A Case Series

Systemic lupus erythematosus (SLE): Pleuropulmonary Manifestations

C h a p t e r 1 3 Interstitial Lung Disease

Manish Powari Regional Training Day 10/12/2014

The connective tissue disorders (CTDs), also. Pivotal clinical dilemmas in collagen vascular diseases associated with interstitial lung involvement

Case 1. Case Presentation. Disclosure Statement. ILD: What the generalist needs to know

Interstitial Lung Disease ILD: Definition

Progress in Idiopathic Pulmonary Fibrosis

Accurate Diagnosis Of Postoperative Pneumonia Requires Objective Data

Combined Unclassifiable Interstitial Pneumonia and Emphysema: A Report of Two Cases

Eosinophilic lung diseases - what the radiologist needs to know

SESSION IV: MECHANISMS OF HUMAN DISEASE: LABORATORY SESSIONS PULMONARY PATHOLOGY I. December 5, 2012

Usual Interstitial pneumonia and Nonspecific Interstitial Pneumonia. Nitra and the Gangs.

Management of idiopathic pulmonary fibrosis: selected case reports

Epidemiology and classification of smoking related interstitial lung diseases

PULMONARY MEDICINE BOARD REVIEW. Financial Conflicts of Interest. Question #1: Question #1 (Cont.): None. Christopher H. Fanta, M.D.

Multidisciplinary Diagnosis in Action: Challenging Case Presentations

Challenges in Pulmonary and Critical Care 2017

Radiologic Approach to Smoking Related Interstitial Lung Disease

ARTICLE IN PRESS. Ahuva Grubstein a, Daniele Bendayan b, Ithak Schactman c, Maya Cohen a, David Shitrit b, Mordechai R. Kramer b,

Regulatory Status FDA-approved indication: Ofev is a kinase inhibitor indicated for the treatment of idiopathic pulmonary fibrosis (IPF) (1).

Disclosures. Traditional Paradigm. Overview 4/17/2010. I have relationships with the following organizations and companies:

Pulmonary Test Brenda Shinar

NONE OVERVIEW FINANCIAL DISCLOSURES UPDATE ON IDIOPATHIC PULMONARY FIBROSIS/IPF (UIP) FOR PATHOLOGISTS. IPF = Idiopathic UIP Radiologic UIP Path UIP

Strategies for Updated Treatment Options for IPF

Current Management of IPF and. Dr R Lakshmi Narasimhan Dept of Pulmonary Medicine

Lung Allograft Dysfunction

Interstitial Pneumonia Related to Undifferentiated Connective Tissue Disease Pathologic Pattern and Prognosis

Nintedanib and Pirfenidone: New Medications in the Management of Idiopathic Pulmonary Fibrosis

Ó Journal of Krishna Institute of Medical Sciences University 99

ILD and systemic disease

USEFULNESS OF HRCT IN DIAGNOSIS AND FOLLOW UP OF PULMONARY INVOLVEMENT IN SYSTEMIC SCLEROSIS

Supplementary Appendix

Controversies in Clinical Trials. Pirfenidone for Idiopathic Pulmonary Fibrosis (IPF)

Eastern Mediterranean Health Journal, Vol. 14, No. 5,

Transcription:

UIP OR NOT UIP PATTERN: THAT IS NOT THE ONLY QUESTION! STÉPHANE JOUNEAU 11 JULY 2014 Respiratory Medicine Department, Pontchaillou Hospital, Rennes, France

CASE OVERVIEW This case highlights how a usual interstitial pneumonia (UIP) pattern may be caused by a number of different pathologies, not just idiopathic pulmonary fibrosis (IPF). In order to make an accurate diagnosis of IPF, it is important to conduct a rigorous clinical primary examination to exclude other pathophysiological causes 2

MEDICAL HISTORY AND TESTS Initial visit (July 2012) Male, 67 years old 90 kg, 175 cm Ex-smoker: 15 pack-years Occupation: Former commercial delegate who travelled regularly to USA, China and North Africa; no history of environmental exposures 3

MEDICAL HISTORY AND TESTS Initial visit (July 2012) Comorbidities: Arterial hypertension, type 2 diabetes, coronary heart disease (stent in 2004), mesenteric infarction (1995) and arthrosis Current medications: Esomeprazole 20 mg, ramipril 5 mg, ASA 75 mg, metoprolol 200 mg, metformin 850 mg, gliclazide 60 mg and simvastatin 20 mg 4

MEDICAL HISTORY AND TESTS Initial visit (July 2012) Physical examination: Chronic productive cough (with mucopurulent sputum) and mild dyspnoea (New York Heart Association Stage I) but no asthenia, anorexia or fever Patient had a history of recurrent lower respiratory tract infections in the past 2 years Blood pressure 120/60 mmhg Heart rate 56 beats per minute SpO 2 (room air) = 98% Bibasilar crackles on lung auscultation Hypereosinophilia = 1700/mm 3 5

IMAGING HRCT scan (August 2012) Pattern recognised: Subpleural, basal predominance Reticular abnormality Honeycombing Absence of features listed as inconsistent with UIP pattern Conclusion = definite UIP pattern 6

IMAGING HRCT (IMAGE 1) HRCT (August 2012) Definite UIP pattern with reticular abnormalities with a subpleural, basal predominance (arrows) 7

IMAGING HRCT (IMAGE 2) HRCT (August 2012) Honeycombing with a subpleural, basal predominance (circles) 8

IMAGING HRCT (IMAGE 3) HRCT (August 2012) Reticular abnormalities (arrows) and honeycombing (circles) with a subpleural, basal predominance 9

IMAGING HRCT (IMAGE 4) HRCT (August 2012) Reticular abnormalities (arrows) and honeycombing (circles) 10

IMAGING HRCT (IMAGE 5) HRCT (August 2012) Reticular abnormalities (arrows) and honeycombing (circles) 11

IMAGING HRCT (IMAGE 6) HRCT (August 2012) Reticular abnormalities (arrows) and honeycombing (circles 12

QUESTIONS Image subscript added, we have obtained the permission to use the image Question 1 If a patient with the signs shown in the photo and a definite UIP pattern on chest CT-scan presents at the clinic complaining of bilateral joints and muscles pains, following a recent occurrence of Raynaud syndrome, what is the most probable diagnosis? Idiopathic pulmonary fibrosis Rheumatoid arthritis with ILD Diffuse erythematous lupus with ILD Anti-synthetase syndrome with ILD [correct answer] Jouneau S., et al. Les manifestations pulmonaires du syndrome des antisynthetases. Revue des Maladies Respiratoires, Elsevier Masson, 2014, in press. Used with permission of the Société de Pneumologie de Langue Française. 13

ANSWERS Answer 1 Although there is a high variability in symptoms and severity, the presence of a number of extra-thoracic manifestations, such as myalgia or muscular deficit, Raynaud s phenomenon, polyarthritis, fever, or mechanics hands in association with interstitial lung disease are all suggestive of antisynthetase syndrome. 1,2 However, positive anti-rna synthetase antibodies (anti-jo1, anti-pl7, and anti-pl12) are required to confirm the diagnosis. 1,2 1 Solomon J, et al. J Bras Pneumol. 2011;37(1):100 109; 2 Fischer A, et al. Respir Med. 2009;103(11):1719-24. 14

LUNG FUNCTION Lung function measurements (August 2012) Overall, lung function/gas exchange appeared to be good There were no signs of infection or connective tissue disease Results of bronchoalveolar lavage appeared normal; however, additional blood tests revealed an increasing eosinophil count A 6-minute walk test was not performed

LUNG FUNCTION Lung function measurements (August 2012) Parameter FEV 1 /FVC FEV 1 FVC DLCO Value (% of predicted) 89% predicted 117% predicted 98% predicted 62% predicted 16

LABORATORY Laboratory results Blood eosinophil count: 2200/mm 3 in August 2012; 2700/mm 3 in September 2012 Parameter Antinuclear antibody Rheumatoid factor Anti-cyclic citrullinated peptide antibodies Anti-neutrophil cytoplasmic antibodies Results Negative Negative Negative Negative 17

BRONCHOSCOPY Bronchoscopy results Normal bronchial tree with no macroscopic anomalies observed BAL differential cell count: Parameter Total cell count Value 3.4 10 6 cells/ml Alveolar macrophages 87% Lymphocytes 12% Neutrophils 1% Eosinophils 0% Ø Normal BAL differential count, no hypereosinophilia on BAL 18

QUESTIONS Question 2 What would make you suspect another diagnosis other than IPF? Possible UIP pattern on chest CT-scan Probable UIP pattern on pulmonary histology Numerous long-term medications 42 year-old patient [correct answer] 19

ANSWERS Answer 2 Because IPF is rare before the age of 50, the index of suspicion for an underlying connective tissue disease should be high. 1 In such a young patient, you have to be very careful with the diagnosis of IPF. The patient should be promptly referred to a lung transplant centre and evaluated for specific telomerase mutations ie, SFPC, SFPB, GATA-2. 2 1 Spagnolo P, et al. Multidisciplinary Respiratory Medicine 2012;7:42; 2 Savage S, and Bertuch A. Genetics in Medicine 2010;12:753 764. 20

MEDICAL HISTORY AND TESTS Follow-up (July 2013) Similar to on first presentation; however, the patient s dyspnoea had worsened (New York Heart Association Stage II) Laboratory findings were also similar to those observed on initial presentation with the exception of the patient s eosinophil count, which had increased 3500/mm 3 in July 2013 5700/mm 3 in September 2013 Raised suspicion of possible Churg-Strauss syndrome or parasitic infection such as aspergillosis, ascaridosis, lymphatic filariasis, distomatosis, trichinosis, toxocaris, strongyloides Also possibility of other connective tissue diseases e.g. rheumatoid arthritis or systemic lupus erythematosus 21

IMAGING HRCT scan (July 2013) Consistent with a definite UIP pattern, including Reticular abnormalities 22

IMAGING HRCT (IMAGE 1) HRCT (July 2013) Reticular abnormalities 23

IMAGING HRCT (IMAGE 2) HRCT (July 2013) Honeycombing 24

IMAGING HRCT (IMAGE 3) HRCT (July 2013) Reticular abnormalities (arrows) and honeycombing (circles 25

IMAGING HRCT (IMAGE 4) HRCT (July 2013) Reticular abnormalities (arrows) and honeycombing (circles 26

IMAGING HRCT (IMAGE 5) HRCT (July 2013) Reticular abnormalities (arrows) and honeycombing (circles 27

IMAGING HRCT (IMAGE 6) HRCT (July 2013) Reticular abnormalities (arrows) and honeycombing (circles 28

LUNG FUNCTION Lung function measurements (July 2013) Parameter FEV 1 /FVC FEV 1 FVC TLC DLCO Value (% of predicted) 86% predicted 105% predicted 90% predicted 86% predicted 57% predicted Parameter Value (absolute) ph 7.48 PaO 2 92 mmhg PaCO 2 35 mmhg CO 2 24% SaO 2 97% Slight decline in lung function from previous visit 29

LUNG FUNCTION Lung function measurements (July 2013) Results of 6-minute walk test (room air): 480 m without pause, no desaturation (100% à 99%); Borg 2 à 3 30

LABORATORY Haematology results (September 2013) To exclude other causes such as Churg Strauss syndrome or parasitic infections a myelogram, osteomedullar biopsy and medullary karyotyping were conducted All tests appeared normal Furthermore, and because there was a suspicion of hypereosinophilic syndrome the patient was genotyped Genotyping identified an FIP1L1-PDGFRα fusion gene 31

DIAGNOSIS 1. HRCT scans revealed a UIP pattern suggestive of IPF; however, the patient s lung function remained relatively stable throughout 2. Laboratory tests revealed an increasing eosinophil count 3. Following genotyping an FIP1L1-PDGFRα fusion gene was identified The patient was diagnosed as having either IPF and hypereosinophilic syndrome or hypereosinophilic syndrome with lung fibrosis Imatinib was initiated 32

LEARNINGS FROM THE CASE 1. Demonstrates the importance of a thorough clinical examination, including physical examination, laboratory tests and blood work-up, and HRCT in the diagnosis of interstitial lung diseases 2. Highlights that, in complex cases, a pulmonologist must also think like an internist and consider pulmonary manifestations of other diseases 33